6/12/2014 9:52:18 AM
SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, today issued the following letter from Punit Dhillon, President and CEO, to the company’s shareholders:
A Letter to Our Shareholders
This is an important moment in cancer immunotherapy and we believe OncoSec is poised to make a real impact. During this pivotal time, it is important that we outline the core fundamentals of our company and our technology, so that you as shareholders will understand why all of us here at OncoSec are excited for the future.
Help employers find you! Check out all the jobs and post your resume.
comments powered by